Indegene Limited has informed the Exchange regarding a press release dated April 29, 2026, titled "Indegene Reports 32.8% YoY Growth in Q4FY26, Crosses ₹1,000 Crore Quarterly Revenue and ₹3,500 Crore Annual Revenue Milestone".
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty Smallcap 250 and 1.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indegene reported strong Q4 FY26 results with revenue of ₹10,034 million (USD 109.7 million), up 32.8% YoY in INR terms. The company crossed the ₹1,000 crore quarterly revenue milestone for the first time and achieved ₹3,500 crore annual revenue. Adjusted EBITDA for Q4 stood at ₹1,889 million at 18.8% margin, while full-year FY26 EBITDA was ₹6,793 million at 19.4% margin. Cash flow from operations surged 47.3% YoY to ₹6,508 million with a cash conversion ratio of 162%. The Board recommended a final dividend of ₹2.25 per share, up 12.5% YoY. The company highlighted 53 clients contributing over $1 million in annual revenue and a strong bookings quarter with 1 deal above $3 million ACV and 7 deals in the $1-3 million range.
Strong revenue growth and cash generation signal solid execution, though EBITDA margins showed slight compression from 20.3% to 18.8% QoQ. The dividend increase and healthy cash flows are positive for shareholders, indicating confidence in business fundamentals entering FY27.